MAIA Biotechnology Announces Publication of Interim Clinical Data on Telomere Targeting Anticancer Agent in Peer-Reviewed Journal Cells
MAIA Biotechnology (NYSE American: MAIA) announced the publication of interim clinical data from its Phase 2 THIO-101 trial in the peer-reviewed journal Cells. The manuscript, focused on "Perioperative Management of Non-Small Cell Lung Cancer in the Era of Immunotherapy," was authored by researchers from Turkey and the U.S., including MAIA's scientific team.
The publication highlights MAIA's novel combination strategy using ateganosine sequenced with a checkpoint inhibitor, which has shown promising results in addressing the challenge of patient resistance to conventional immunotherapies. This development represents a potential breakthrough for patients with high unmet medical needs in non-small cell lung cancer treatment.
MAIA Biotechnology (NYSE American: MAIA) ha annunciato la pubblicazione su Cells di dati clinici intermedi del suo studio di Fase 2 THIO-101. Il manoscritto, intitolato "Gestione perioperatoria del carcinoma polmonare non a piccole cellule nell'era dell'immunoterapia", 猫 stato redatto da ricercatori turchi e statunitensi, incluso il team scientifico di MAIA.
La pubblicazione mette in luce la strategia combinata innovativa di MAIA basata su ateganosina sequenziata con un inibitore del checkpoint, che ha mostrato risultati promettenti nel superare la resistenza dei pazienti alle immunoterapie convenzionali. Questo progresso potrebbe rappresentare una svolta per i pazienti con grandi bisogni terapeutici insoddisfatti nel trattamento del carcinoma polmonare non a piccole cellule.
MAIA Biotechnology (NYSE American: MAIA) anunci贸 la publicaci贸n en la revista Cells de datos cl铆nicos interinos de su ensayo de Fase 2 THIO-101. El manuscrito, titulado "Manejo perioperatorio del c谩ncer de pulm贸n de c茅lulas no peque帽as en la era de la inmunoterapia", fue elaborado por investigadores de Turqu铆a y EE. UU., incluido el equipo cient铆fico de MAIA.
La publicaci贸n destaca la novedosa estrategia combinada de MAIA que emplea ateganosina secuenciada con un inhibidor del checkpoint, la cual ha mostrado resultados prometedores para afrontar la resistencia de los pacientes a las inmunoterapias convencionales. Este avance podr铆a suponer un hito para pacientes con necesidades m茅dicas no cubiertas en el tratamiento del c谩ncer de pulm贸n de c茅lulas no peque帽as.
MAIA Biotechnology (NYSE American: MAIA)電� 霃欕鞁偓 鞝�雱� Cells鞐� 鞛愳偓鞚� 2靸� THIO-101 鞛勳儊 欷戧皠 雿办澊韯半ゼ 瓴岇灛頄堧嫟瓿� 氚滍憸頄堨姷雼堧嫟. "氅挫棴頃晹鞝� 鞁滊寑鞚� 牍勳唽靹疙彫韽愳晹 靾橃垹 欤茧硛 甏�毽�(Perioperative Management of Non-Small Cell Lung Cancer in the Era of Immunotherapy)"霛茧姅 鞝滊鞚� 鞗愱碃電� 韯绊偆鞕� 氙戈淡 鞐瓣惮歆�, 攴鸽Μ瓿� MAIA 瓿柬暀韺�鞚� 瓿惦彊 鞝�鞛愲 彀胳棳頄堨姷雼堧嫟.
頃措嫻 瓴岇灛電� 觳错伂韽澑韸� 鞏奠牅鞝滌檧 靾滌皑 韴棳霅橂姅 鞎勴厡臧�雲胳嫚(ateganosine)鞚� 頇滌毄頃� MAIA鞚� 順侅嫚鞝� 氤戩毄 鞝勲灥鞚� 臁半獏頃橂┌, 旮办〈 氅挫棴旃橂鞐� 雽�頃� 頇橃瀽 鞝�頃劚鞚� 攴闺车頃橂姅 雿� 鞙犽頃� 瓴瓣臣毳� 氤挫榾雼り碃 鞝勴暕雼堧嫟. 鞚� 臧滊皽鞚� 牍勳唽靹疙彫韽愳晹 旃橂鞐愳劀 雴掛潃 氙胳订臁� 鞚橂 靾橃殧毳� 臧�歆� 頇橃瀽霌れ棎瓴� 須嶊赴鞝� 鞝勴櫂鞝愳澊 霅� 臧�電レ劚鞚� 鞛堨姷雼堧嫟.
MAIA Biotechnology (NYSE American: MAIA) a annonc茅 la publication dans la revue Cells des donn茅es cliniques interm茅diaires de son essai de phase 2 THIO-101. Le manuscrit, intitul茅 "Prise en charge p茅riop茅ratoire du cancer du poumon non 脿 petites cellules 脿 l'猫re de l'immunoth茅rapie", a 茅t茅 r茅dig茅 par des chercheurs de Turquie et des 脡tats-Unis, incluant l'茅quipe scientifique de MAIA.
La publication met en avant la strat茅gie combinatoire novatrice de MAIA utilisant l'ateganosine en s茅quence avec un inhibiteur de checkpoint, qui a montr茅 des r茅sultats prometteurs pour surmonter la r茅sistance des patients aux immunoth茅rapies classiques. Cette avanc茅e pourrait constituer une perc茅e pour les patients pr茅sentant des besoins m茅dicaux non satisfaits dans le traitement du cancer du poumon non 脿 petites cellules.
MAIA Biotechnology (NYSE American: MAIA) gab die Ver枚ffentlichung von Zwischenresultaten aus der Phase-2-Studie THIO-101 in der Fachzeitschrift Cells bekannt. Das Manuskript mit dem Titel "Perioperative Behandlung des nicht-kleinzelligen Lungenkrebses im Zeitalter der Immuntherapie" wurde von Forschern aus der T眉rkei und den USA verfasst, darunter das Wissenschaftsteam von MAIA.
Die Publikation hebt MAIAs neuartige Kombinationsstrategie hervor, die ateganosin in Sequenz mit einem Checkpoint-Inhibitor einsetzt und vielversprechende Ergebnisse bei der 脺berwindung der Patientenresistenz gegen眉ber herk枚mmlichen Immuntherapien zeigt. Diese Entwicklung k枚nnte einen Durchbruch f眉r Patienten mit hohem ungedecktem medizinischem Bedarf bei der Behandlung des nicht-kleinzelligen Lungenkrebses darstellen.
- None.
- Clinical trial still in Phase 2, indicating long path to potential approval
- No specific efficacy data or success metrics provided in the announcement
CHICAGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (鈥淢AIA鈥�, the 鈥淐ompany鈥�), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that a manuscript detailing developments in its Phase 2 THIO-101 clinical trial was accepted and published in the international peer-reviewed open access scientific journal, , in a special issue, 鈥淐ellular Mechanisms of Anti-Cancer Therapies鈥�
The manuscript, titled 鈥�,鈥� was authored by a group of oncology researchers in Turkey and the U.S. including MAIA scientists Sergei Gryaznov, Ph.D., Chief Scientific Officer and Ilgen Mender, Director of Biology Research, along with MAIA Scientific Advisory Board members Z. Gunnur Dikmen, M.D., Ph.D. and Saadettin Kili莽kap, M.D., M.Sc.
MAIA Chairman and CEO Vlad Vitoc, M.D. commented, 鈥淭he importance of the findings published in Cells cannot be overstated. While conventional immunotherapies have expanded treatment options for patients, intrinsic and acquired resistance by patients remains a challenge. Our novel combination strategy of ateganosine sequenced with a checkpoint inhibitor stands out, showing encouraging results in a population with high unmet medical need.鈥�
About Cells
Cells聽(ISSN 2073-4409) is an international, peer-reviewed, open access journal which provides an advanced forum for studies related to cell biology, molecular biology and biophysics. It publishes reviews, research articles, communications and technical notes.聽Cells is an MDPI聽(Multidisciplinary Digital Publishing Institute) publication.
About Ateganosine
Ateganosine (THIO, 6-thio-dG or 6-thio-2鈥�-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2鈥�-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type鈥搒pecific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.
About MAIA Biotechnology, Inc.
MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit .
Forward Looking Statements
MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry鈥檚 actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as 鈥渕ay,鈥� 鈥渕ight,鈥� 鈥渨ill,鈥� 鈥渟hould,鈥� 鈥渃ould,鈥� 鈥渆xpect,鈥� 鈥減lan,鈥� 鈥渁nticipate,鈥� 鈥渂elieve,鈥� 鈥渆stimate,鈥� 鈥減roject,鈥� 鈥渋ntend,鈥� 鈥渇uture,鈥� 鈥減otential,鈥� or 鈥渃ontinue,鈥� and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, 鈥淢AIA,鈥� 鈥淐ompany,鈥� 鈥渨e,鈥� 鈥渙ur,鈥� and 鈥渦s鈥� refers to MAIA Biotechnology, Inc. and its subsidiaries.
Investor Relations Contact
+1 (872) 270-3518
FAQ
What are the key findings of MAIA Biotechnology's Phase 2 THIO-101 trial published in Cells?
How does MAIA Biotechnology's new cancer treatment approach differ from conventional immunotherapies?
Who are the key researchers involved in MAIA Biotechnology's cancer treatment study?
What type of cancer does MAIA Biotechnology's THIO-101 trial target?
What is the current development stage of MAIA Biotechnology's cancer treatment?
